CLL-1 CAR T-cells

CLL-1 CAR T-cells are autologous chimeric antigen receptor T-cell therapies engineered to recognize human C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A), an antigen highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells but largely absent from normal hematopoietic stem cells. In these products, patient T cells are collected, transduced ex vivo with a CAR construct (typically containing an anti–CLL-1 single-chain variable fragment, a costimulatory domain such as CD28 or 4-1BB, and CD3ζ signaling), expanded, and reinfused after lymphodepleting chemotherapy. Phase I trials in relapsed/refractory AML have shown high complete remission rates and manageable toxicity profiles dominated by cytokine release syndrome, with emerging variants such as PD-1 knockdown CLL-1 CAR T-cells and dual-target CARs further enhancing potency and persistence. Development is primarily focused on CLL-1–positive relapsed/refractory AML, with preclinical exploration in myelomonocytic leukemias and other CLL-1–expressing myeloid malignancies.[1][4][5][9][10]

Other names

CLL1 CAR-T cellsCLL-1 CAR-T cellsCLL 1 CAR-T cellsCLL1 CAR-TCLL-1 CAR-TCLL 1 CAR-TCLL-1 chimeric antigen receptor T cellsCLL1 chimeric antigen receptor T cellsCLL 1 chimeric antigen receptor T cellsCLL-1-targeted CAR T cellsCLL1-targeted CAR T cellsCLL 1-targeted CAR T cells